Priyank Yagnik1, Apurva Jain2, Jason K Amponsah3, Parth Bhatt2, Narendrasinh Parmar4, Keyur Donda5, Mayank Sharma6, Mihir Dave7, Riddhi Chaudhari8, Tetyana L Vasylyeva2, Fredrick Dapaah-Siakwan9. 1. Department of Pediatrics, School of Medicine, University of Kansas, Wichita, Kansas. 2. Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, Texas. 3. Department of Medicine, The Trust Hospital, Accra, Ghana. 4. Department of Pediatrics, Brookdale University Hospital Medical Center, Brooklyn, New York. 5. Department of Pediatrics, University of South Florida, Tampa, Florida. 6. Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, Florida. 7. Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, New York. 8. Department of Pediatrics, University of Connecticut, Farmington, Connecticut; and. 9. Section of Neonatology, Valley Children's Healthcare, Madera, California fdapaahsiakwan@valleychildrens.com.
Abstract
OBJECTIVES: We examined the trends in the rate of Henoch-Schönlein purpura (HSP) hospitalizations and the associated resource use among children in the United States from 2006 through 2014. METHODS: Pediatric hospitalizations with HSP were identified by using International Classification of Diseases, Ninth Revision, code 287.0 from the National Inpatient Sample. HSP hospitalization rate was calculated by using the US population as the denominator. Resource use was determined by length of stay (LOS) and hospital cost. We used linear regression for trend analysis. RESULTS: A total of 16 865 HSP hospitalizations were identified, and the HSP hospitalization rate varied by age, sex, and race. The overall HSP hospitalization rate was 2.4 per 100 000 children, and there was no trend during the study period. LOS remained stable at 2.8 days, but inflation-adjusted hospital cost increased from $2802.20 in 2006 to $3254.70 in 2014 (P < .001). CONCLUSIONS: HSP hospitalization rate in the United States remained stable from 2006 to 2014. Despite no increase in LOS, inflation-adjusted hospital cost increased. Further studies are needed to identify the drivers of increased hospitalization cost and to develop cost-effective management strategies.
OBJECTIVES: We examined the trends in the rate of Henoch-Schönlein purpura (HSP) hospitalizations and the associated resource use among children in the United States from 2006 through 2014. METHODS: Pediatric hospitalizations with HSP were identified by using International Classification of Diseases, Ninth Revision, code 287.0 from the National Inpatient Sample. HSP hospitalization rate was calculated by using the US population as the denominator. Resource use was determined by length of stay (LOS) and hospital cost. We used linear regression for trend analysis. RESULTS: A total of 16 865 HSP hospitalizations were identified, and the HSP hospitalization rate varied by age, sex, and race. The overall HSP hospitalization rate was 2.4 per 100 000 children, and there was no trend during the study period. LOS remained stable at 2.8 days, but inflation-adjusted hospital cost increased from $2802.20 in 2006 to $3254.70 in 2014 (P < .001). CONCLUSIONS:HSP hospitalization rate in the United States remained stable from 2006 to 2014. Despite no increase in LOS, inflation-adjusted hospital cost increased. Further studies are needed to identify the drivers of increased hospitalization cost and to develop cost-effective management strategies.